| Literature DB >> 36119429 |
Sushma Yadav Boorgula1, Sadhana Yelamanchili1, Pragathi Kottapalli1, Mohini D Naga1.
Abstract
Introduction Since coronavirus disease 2019 (COVID-19) has limited treatment options, concern has been raised over secondary infections and antimicrobial resistance (AMR) patterns. It has been observed that patients who were infected with COVID-19 were predisposed to develop secondary infections. The purpose of the study is to ascertain the prevalence of the bacterial and fungal coinfections in COVID-19 patients, and also to assess the AMR patterns in the obtained isolates. Methods We have studied 200 clinical samples obtained from 122 COVID-19 positive patients. Pathogens were identified using Vitek 2 system. The demographic and clinical patterns were also observed. Results A total of 122 patients developed secondary infections. Patients aged more than 40 years were majorly affected ( p -value < 0.0001). Respiratory samples ( n = 96) were predominant. Klebsiella pneumoniae ( n = 68) was the most common pathogen isolated followed by Acinetobacter baumannii ( n = 54) and an overall 6% rise in the Carbapenem resistance was observed in the isolates. Conclusion To contain the secondary infections in COVID-19 patients, it is imperative to adhere to antimicrobial stewardship program and timely revise the empirical antibiotic policy. The Indian Association of Laboratory Physicians. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. ( https://creativecommons.org/licenses/by-nc-nd/4.0/ ).Entities:
Keywords: antimicrobial resistance; central line associated bloodstream infections; coagulase-negative staphylococcus
Year: 2022 PMID: 36119429 PMCID: PMC9473943 DOI: 10.1055/s-0041-1741438
Source DB: PubMed Journal: J Lab Physicians ISSN: 0974-2727
Susceptibility percentage for various antibiotics observed
|
Nonfermenters (
|
Pseudomonas (
| ||||
|---|---|---|---|---|---|
| Amoxycillin-clavulanate | 18.2 | 16.8 | – | – | |
| Piperacillin-tazobactam | 19.6 | 3.84 | 43.75 | – | 87.5 |
| Cefoperazone-sulbactam | 23.8 | 5.55 | 58.33 | – | 87–5 |
| Ceftazidime | 11.11 | 0.03 | 35.29 | – | 87.5 |
| Cefepime | 21.21 | 5.55 | 33.33 | – | 87.5 |
| Imipenem | 27.11 | 5.66 | 47.05 | – | 87.5 |
| Meropenem | 23.5 | 5.76 | 56 | – | 87.5 |
| Ciprofloxacin | 7.69 | – | 16 | – | 87.5 |
| Levofloxacin | 6.15 | 5.88 | 18.75 | 46.66 | 87.5 |
| Amikacin | 33.8 | 11.11 | 40 | – | 100 |
| Tigecycline | 56 | 66.66 | 84 | – | – |
| Colistin | 75.7 | 98.14 | 75 | – | 100 |
| Trimethoprim-sulfamethoxazole | 23 | – | 47.82 | 85.71 | – |
Demographics, infections, timing of outcome, and culture results
| % or IQR | ||
|---|---|---|
| Age, years, median (IQR) | 58 | 51.67 |
| Sex | ||
| Males | 95 | 77.2% |
| Females | 27 | 22.13% |
| Infection | ||
| Respiratory | 66 | 54% |
| Bloodstream | 40 | 32.7% |
| Others | 16 | 13.3% |
| Outcomes | ||
| Average length of stay | 10.7 days | |
| Discharged | 52 | 42.6% |
| Deceased | 67 | 54.9% |
| Still admitted to hospital | 3 | 2.45% |
Abbreviation: IQR, interquartile range.
Fig. 1Bacteria and fungus profile.